Lupin stock gets FDA approval as Q1 revenue jumps 32 percent

Published on 09/29/2026 at 14:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lupin stock now has tentative U.S. FDA approval for an apixaban suspension announced September 28, 2026. Q1 FY27 adjusted PAT reached INR 14.15 billion.

Lupin, INE326A01037, Illustration mit AI erstellt.

Lupin (ISIN INE326A01037) reported Q1 FY27 revenue of INR 82.77 billion, up 32.00 percent year over year, as the company added a new U.S. regulatory milestone. The result and the approval of an apixaban oral suspension give Lupin stock two concrete growth markers for the September 29, 2026 market session.

Apixaban adds a pipeline milestone

According to Lupin on September 28, 2026, the U.S. FDA granted tentative approval for a 1.25 mg/mL apixaban oral suspension through the 505(b)(2) pathway. The liquid formulation is designed for adults who require anticoagulation therapy and may have difficulty swallowing tablets.

The product is intended for manufacture at Lupin's Somerset, New Jersey facility after final approval. That detail links the regulatory milestone to an existing U.S. production base rather than to a purely development-stage asset.

Q1 growth came with a margin test

DSIJ reported on August 10, 2026, that Prabhudas Lilladher retained an Accumulate rating after Q1 FY27. Revenue was 5.00 percent above the broker's INR 79.04 billion estimate, while EBITDA rose 50.10 percent year over year to INR 24.64 billion and adjusted PAT increased 16.10 percent to INR 14.15 billion.

EBITDA margin reached 29.80 percent in Q1 FY27 versus 26.20 percent in Q1 FY26. The same report said management guided for FY27 U.S. revenue of USD 1.1-1.2 billion and reiterated an EBITDA margin guide of 25.00 percent, making competitive pressure the key counter-factor to the pipeline story.

Market value stays below yearly high

Lupin was last at INR 2,052.10 on the NSE on September 29, 2026 at 3:15 p.m. IST. Its market capitalization was INR 938.3 billion, while the 52-week range stood at INR 1,900.00 to INR 2,529.50, leaving the latest quoted value INR 477.40 below the yearly high.